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Abstract:  Multiple lines of evidence indicate that hypofunction of glutamatergic neurotransmission via N-methyl-D-
aspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia, suggesting that increasing 
NMDA receptor function via pharmacological manipulation could provide a new strategy for the management of 
schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets 
for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the 
availability of the obligatory co-agonist glycine at modulatory sites on the NMDA receptors through the inhibition of 
glycine transporter-1 (GlyT-1) on glial cells. Clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-
methyl glycine) shows antipsychotic activity in patients with schizophrenia. Accordingly, a number of pharmaceutical 
companies have developed novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. This paper provides 
an overview of the various GlyT-1 inhibitors and their therapeutic potential.  
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INTRODUCTION 
  A growing body of evidence suggests that the N-methyl-
D-aspartate (NMDA) receptors (Fig. 1 ) play a role in the 
pathophysiology of schizophrenia [1-12]. Subanesthetic 
doses of the non-competitive NMDA receptor antagonist 
phencyclidine (PCP; Fig. 2) have been shown to produce a 
wide range of transient schizophrenia-like symptoms, 
including estrangement, loss of body boundaries, formal 
thought disorder, hallucinations, and psychosis [1,13,14]. In 
addition, PCP is known to dramatically exacerbate the 
symptoms of schizophrenia [1,13,14]. In a randomized, 
double-blind, placebo-controlled study, Krystal and co-
workers [15] reported that the non-competitive NMDA 
receptor antagonist ketamine (Fig. 2) produced positive and 
negative symptoms in a dose-dependent manner. A high 
dose of ketamine elicited significant perceptual effects, 
including altered perceptions of the body, environment, and 
time. In another double-blind, placebo-controlled study, 
Malhotra et al. [16] reported that ketamine produced brief 
psychosis marked by thought disorder and withdrawal-
retardation in healthy volunteers. Furthermore, a double-
blind, crossover-design study revealed that ketamine alters 
mood in healthy volunteers [17]. Moreover, in a double-
blind, placebo-controlled study, Lahti et al. [18] reported 
that ketamine induced a brief (less than 30 minutes), dose-
related worsening of positive symptoms in schizophrenic 
patients maintained on haloperidol. In contrast, Zarate et al. 
[19] demonstrated the robust and rapid (within 2 h) 
antidepressant effects of a single dose of ketamine (0.5   
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mg/kg, i.v. infusion for 40 min) in treatment-resistant major 
depression, suggesting the role of NMDA receptors in the 
rapid antidepressant activity of ketamine [20-22]. 
  In addition to glutamate, the NMDA receptors are 
modulated by glycine, D-serine, polyamines, and specific 
divalent cations, including magnesium and zinc [9-12] (Fig. 
1). Glycine and D-serine (Fig. 3 ) act as obligatory co-
agonists at the glycine modulatory sites on the NMDA 
receptors to regulate glutamatergic transmission. Currently, 
the glycine modulatory sites on the NMDA receptors are the 
most attractive therapeutic targets for schizophrenia. This 
review article provides an overview of glycine transporter-1 
(GlyT-1) inhibitors as a potential therapeutic approach to the 
treatment of schizophrenia.  
GLYCINE 
 Glycine  (Fig. 3 ) was first proposed to act as a 
neurotransmitter in the mammalian spinal cord in 1965 [23]. 
Glycine is now among the well-characterized amino acid 
neurotransmitters in the mammalian CNS, where it is known 
to act as an inhibitory transmitter via its interaction with 
strychnine-sensitive glycine receptors [24-29]. It also plays 
an important role in excitatory neurotransmission via 
strychnine-insensitive glycine sites located on the NMDA 
receptors [26-29].  
  The plasma levels of total serine (L- and D-serine) and 
glycine in patients with schizophrenia are higher than those 
of controls [30], and the levels of serine and glycine in the 
brains of schizophrenic patients are higher than those of 
controls [30,31], suggesting a possible abnormality in serine 
hydroxymethyltransferase, by which glycine is converted to 
L-serine [10]. Interestingly, it has been reported that serum 
D-serine levels and the D-serine/total serine ratio in patients 
with schizophrenia are significantly lower than those of Glycine Transport Inhibitors for the Treatment of Schizophrenia  The Open Medicinal Chemistry Journal, 2010, Volume 3    11 
healthy control subjects, supporting the hypothesis of 
NMDA receptor hypofunction in schizophrenia [8]. 
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Fig. (2). Chemical structures of phencyclidine (PCP), ketamine, and 
dizocilpine ((+)-MK-801). 
 
  Given the NMDA receptor hypofunction hypothesis of 
schizophrenia, increasing NMDA receptor function by 
glycine may be a potential strategy for the management of 
schizophrenia. Recent retrospective analyses have suggested 
that NMDA receptor agonists are effective at the treatment 
of persistent negative symptoms and cognitive deficits of 
schizophrenia, and that the full agonist glycine may be more 
effective than the partial agonist D-cycloserine (Fig. 3) [32].  
GLYCINE TRANSPORTER (GLyT) 
  In the CNS, synaptic levels of glycine are regulated by 
specific sodium/chloride-dependent transporters. The effects 
of glycine in the synapse are terminated by its rapid reuptake 
into the nerve terminal and adjacent glial cells via high-
affinity glycine transporters referred to as GlyT-1 and GlyT-
2. GlyT-1 and GlyT-2 possess 12 putative transmembrane 
spanning domains, and share approximately 50% amino acid 
sequence identity [26-29,33,34]. GlyT-1 is widely expressed 
in the CNS, where it is predominantly present on glial cells. 
It is likely that GlyT-1 is responsible for glycine reuptake in 
forebrain areas, and in some regions, it may be co-localized 
with strychnine-insensitive glycine modulatory sites on the 
NMDA receptors [33-39]. A recent study demonstrated that 
glycine transport might maintain local synaptic glycine at 
very low levels, suggesting that GlyT-1 could play a role in 
regulating glutamatergic neurotransmission via NMDA 
receptors [40]. In contrast to GlyT-1, GlyT-2 has a 
predominantly neuronal and more limited distribution, being 
primarily restricted to the spinal cord, brainstem, and 
cerebellum [38]. Indeed, GlyT-2 is known to be co-localized 
with strychnine-sensitive glycine receptors, suggesting that 
GlyT-2 may be a reliable marker for glycinergic neurons 
[26-29]. 
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Fig. (3). Chemical structures of glycine, sarcosine (N-methyl 
glycine), D-serine, and D-cycloserine 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The NMDA receptor complex Glutamate and NMDA bind to the agonist site on NMDA receptors. Phencyclidine (PCP), ketamine, 
and dizocilpine ((+)-MK-801) bind to PCP-receptor in the inside of the NMDA receptors. Glycine and D-serine bind to co-agonist site 
(glycine modulatory site) on the NMDA receptors. 
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   In an attempt to clarify the in vivo functional roles of 
glycine transporters in the CNS, knockout mice deficient in 
the GlyT-1 gene have been generated [41,42]. Newborn mice 
deficient in the GlyT-1 gene are anatomically normal, but 
show severe motor and respiratory deficits and die during the 
first postnatal day [41]. Glycine or the GlyT-1 inhibitor 
sarcosine (N-methyl glycine; Fig. 3) were found to suppress 
respiratory activity in slices from wild-type mice. During 
early postnatal life, GlyT-1 is essential for regulating glycine 
levels at inhibitory glycine receptors, and GlyT-1 deletion 
generates symptoms found in human glycine encephalopathy 
[41]. Furthermore, heterozygous knockout mice (reduced 
expression of GlyT-1) show enhanced hippocampal NMDA 
receptor function and memory retention, and are protected 
against disruptions of sensory gating induced by 
amphetamine, which suggests that GlyT-1 inhibitors might 
bring about both cognitive enhancement and antipsychotic 
effects [42]. Mice heterozygous for the GlyT-1 gene show 
faster decay kinetics, reduced ifenprodil sensitivity, and 
increased zinc-induced antagonism in NMDA receptor 
currents [42]. These findings highlight the importance of 
GlyT-1 in the regulation of glutamatergic neurotransmission. 
Taken together, the data suggest that increasing synaptic 
levels of glycine by inhibition of its uptake will lead to 
enhanced NMDA receptor activation, in turn suggesting a 
potential role for GlyT-1 inhibitors as a novel treatment for 
schizophrenia [43-55]. 
GLyT-1 INHIBITORS 
  Glycine is an endogenous compound that is actively 
metabolized and sequestered in the brain. Glycine is 
extensively metabolized in the liver, and only poorly crosses 
the blood-brain barrier. Therefore, a large amount of glycine 
is needed for the treatment of schizophrenia [32]. Thus, the 
ability of glycine levels to modulate NMDA receptor-
mediated neurotransmission suggests that the 
pharmacological manipulation of synaptic glycine might be 
effective in the treatment of conditions involving NMDA 
receptor hypofunction [1,43-55]. 
  The NMDA receptor antagonist PCP (Fig. 2) has been 
widely used in studies of animal models of schizophrenia [9-
11,56,57]. We previously reported that repeated 
administration of PCP (10 mg/kg/day for 10 days) caused 
long-term cognitive deficits in mice (more than 6 weeks after 
the final administration of PCP), and that PCP-induced 
cognitive deficits could be improved by subsequent 
subchronic (2 weeks) administration of clozapine, but not 
haloperidol [58]. Therefore, the reversal of PCP-induced 
cognitive deficits may be a potential animal model of 
atypical antipsychotic activity, i.e., this model may be 
beneficial in terms of ameliorating the cognitive deficits in 
people with schizophrenia [59-67]. Using this model, we 
reported that treatment with the selective GlyT-1 inhibitor, 
(R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sa-
rcosine (NFPS, ALX 5407; Fig. 4) [68-71], attenuated PCP-
induced cognitive deficits in mice [64]. We also found that 
repeated administration of PCP caused increased levels of 
GlyT-1 protein in the mouse hippocampus, and that 
extracellular glycine levels in the hippocampus of PCP-
treated mice were lower than those of control mice [64]. 
Furthermore, NFPS inhibited PCP-induced hyperactivity in 
mice, and NFPS reversed PCP-induced changes in 
electroencephalogram (EEG) power spectra in conscious rats 
[71]. It has been reported that NFPS induced a pattern of c-
Fos immunoreactivity comparable with the atypical 
antipsychotic drug clozapine, and that NFPS enhanced 
prepulse inhibition (PPI) of the acoustic startle response in 
DBA/2J mice, a strain with low basal levels of PPI [72]. 
Moreover, to the same degree as by clozapine or D-serine, 
NFPS was able to reverse persistent latent inhibition (LI) 
[72] and cognitive deficits [73] induced by the NMDA 
receptor antagonist dizocilpine ((+)-MK-801; Fig. 2 ). 
Manahan-Vaughan  et al. [74] reported that NFPS could 
rescue hippocampal long-term potentiation and learning 
deficits in freely behaving rats after systemic administration 
of dizocilpine. All these findings suggest that GlyT-1 
inhibitors could potentially serve as therapeutic drugs to treat 
the cognitive deficits associated with schizophrenia. 
  Researchers at Sanofi-Synthelabo Recherche reported the 
detailed neuropharmacological profile of SSR 504734 (Fig. 
5) as part of a biochemical approach to developing a 
selective and reversible GlyT-1 inhibitor [75]. SSR 504734, 
a selective and reversible inhibitor of GlyT-1, blocked the ex 
vivo uptake of glycine in a rapid, reversible, and long-term 
manner. In animal models of schizophrenia, this compound 
normalized spontaneous PPI deficits in DBA/2 mice, and 
reversed both amphetamine-induced locomotor hyperactivity 
as well as selective attention deficits in adult rats treated 
neonatally with PCP. These findings suggest that SSR 
504734 is a potent and selective GlyT-1 inhibitor that 
exhibits ameliorative effects in animal models of 
schizophrenia; this compound may therefore be efficacious 
not only in treating positive, but also negative symptoms 
(i.e., cognitive deficits) of schizophrenia [75]. Moreover, it 
has been reported that SSR 504734 (10 mg/kg) enhanced the 
facilitatory influence of glutamatergic afferents on dopamine 
neurotransmission in the nucleus accumbens, and this 
synergistic effect was found to be dependent on 
glutamatergic tone [76]. Furthermore, SSR 504734 is 
reported to be effective in the PCP-induced functional 
activation in the cortico-limbo-thalamic circuits [77] and 
working memory deficits [78]. Moreover, SSR 504734 
attenuated PCP-induced hyperlocomotion in mice, but 
potentiated the motor stimulant and motor depressant effects 
of amphetamine and apomorphine, respectively [79]. 
 
 
 
 
 
 
 
 
Fig. (4). Chemical structure of (R)-(N-[3-(4'-fluorophenyl)-3-(4'-
phenylphenoxy)propyl])sarcosine (NFPS, ALX 5407). 
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Fig. (5). Chemical structure of SSR 504734 
 
  Recently, researchers at the Sanofi-Synthelabo Rec-
herche Institute reported the detailed neuropharmacological 
profile of SSR 103800, a novel selective and reversible 
GlyT-1 inhibitor. They demonstrated that SSR 103800 
elevates central glycine levels in the prefrontal cortex, and it 
exhibits potential therapeutic activity in animal models 
considered representative of the positive, cognitive, and 
depressive symptoms observed in patients with schizo-
phrenia [80]. SSR 103800 (1 and 3 mg/kg) and SSR 504734 
(1 and 10 mg/kg) potentiated latent inhibition (LI) under 
conditions where LI was not present in non-treated controls 
and SSR 103800 (1 mg/kg) reversed amphetamine-induced 
disrupted LI while not affecting LI on its own. Additionally, 
SSR 103800 (1 and 3 mg/kg) and SSR 504734 (3 and 10 
mg/kg) reversed abnormally persistent LI induced by 
dizocilpine. In the neurodevelopmental model, SSR 504734 
(3 and 10 mg/kg) reverted the LI back to control (normal) 
levels [78]. These preclinical data from acute and 
neurodevelopmental models suggest that GlyT-1 inhibitors 
could exhibit activity in the positive, negative, and cognitive 
symptom domains of schizophrenia. 
  Researchers at Merck Research Laboratories reported the 
pharmacological profile of a class of novel GlyT-1 inhibitors 
related to 4,4-disubstituted piperidines, including 2-
methoxy-N-{1-[4-phenyl-1-(propylsulfonyl)piperidin-4-yl]-
methyl}benzamide (compound 1: Fig. 6 ) and 2-amino-6-
chloro-N-{(1S)-1-[4-phenyl-1-(propylsulfonyl)-piperidin-4- 
yl]ethyl}benzamide (compound 2: Fig. 6) [81,82]. A rapid 
and sustained increase in the extracellular levels of glycine in 
the prefrontal cortex of freely moving rats was observed at 
 
 
 
 
 
Fig. (6). Chemical structure of compound 1 (2-methoxy-N-{[4-phenyl-1-(propylthio)piperidin-4-yl]methyl}benzamide) and compound 2 (2-
amino-6-chloro-N-{(1S)-1-[4-phenyl-1-(propylthio)piperidin-4-yl]ethyl}benzamide). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Chemical structures of compound 3, (1-phenyl-8-[(1S,2S)-2-phenylcyclohexyl]-1,3,8-triazaspiro[4.5]decan-4-one), compound 4, (8-
[(1S,2R)-2-hydroxy-2-phenylcyclohexyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one), compound 5, ((4R)-4-phenyl-8-[(1S,2S)-2-
phenylcyclohexyl]-2,8-diazaspiro[4.5]decan-1-one), compound 6, ((4R)-8-[(1S,2R)-2-hydroxy-2-phenylcyclohexyl]-4-phenyl-2,8-
diazaspiro[4.5]decan-1-one), and compound 7, (4-(4-fluorophenyl)-8-[1-(4-fluorophenyl)cyclohexyl]-2,8-diazaspiro[4.5]decan-1-one). 
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all three experimental doses (1, 3, 10 mg/kg, s.c.) of this 
compound. Furthermore, this compound was found to 
significantly enhance PPI at three different doses (3, 30, 100 
mg/kg, s.c.) in DBA/2J mice. Brain levels of this compound 
ranged from 400 nM to 2300 nM during the time course of 
the PPI experiments. By selectively increasing extracellular 
glycine levels in the prefrontal cortex via the inhibition of 
GlyT-1, this compound significantly enhanced performance 
in a behavioral animal model of sensorimotor gating [81].  
  Researchers at F. Hoffmann-La Roche, Ltd. reported a 
novel series of N-(2-aryl-cyclohexyl) substituted 
spiropiperidines (compound 3-7: Fig. 7) as highly selective 
GlyT-1 inhibitors [83-87]. Furthermore, a potent and 
selective GlyT-1 inhibitor 4-(4-{[2-(cyclopropylmethoxy)-5-
(methylsulfonyl)phenyl]carbonyl}piperazin-1-yl)-3-
fluorobenzonitrile (compound 8: EC50 = 16 nM for GlyT-
1)(Fig. 8) increased extracellular glycine levels in the mouse 
striatum after oral administration [88]. 
  Researchers at H. Lundbeck A/S developed the 
compound (R)-4-[5-chloro-2-(4-methoxy-phenylsulfanyl)-
phenyl]-2-methyl-piperazin-1-yl-acetic acid (compound 9: 
IC50 = 150 nM) (Fig. 9 ), which was shown to elevate 
extracellular glycine levels in the rat ventral hippocampus, as 
measured by in vivo microdialysis at doses of 1.2-4.6 mg/kg 
(s.c.) [89]. Furthermore, the same group reported the new 
compound (S)-1-{2-[3-(3-fluoro-phenylsulfanyl)biphenyl-4-
yloxy]ethyl}pyrrolidine-2-carboxylic acid (compound 10: 
IC50 = 59 nM) [90] (Fig. 9). In vitro and in vivo assessments 
revealed that the CNS utility of this class of compounds 
might be diminished due to active efflux transporter activity 
[90]. 
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Fig. (8). Chemical structure of compound 8, 4-(4-{[2-
(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]carbonyl}piperaz-
in-1-yl)-3-fluorobenzonitrile. 
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Fig. (9). Chemical structure of compound 9, (R)-4-[5-chloro-2-(4-
methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acetic 
acid and compound 10, (S)-1-{2-[3-(3-fluoro-phenylsulfanyl) 
biphenyl-4-yloxy]ethyl}pyrrolidine-2-carboxylic acid. 
  ORG 25935 (cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-
tetrahydronaphthalen-2- ylmethyl)amino-methylcarboxylic acid 
hydrochloride)( Fig. 10) is a GlyT-1 inhibitor that easily crosses 
the blood-brain barrier. ORG 25935 (6 mg/kg, i.p.) was shown 
to increase striatal extracellular glycine levels by ~50-80% for 
~2.5 hours [91]. Molander et al. [92] reported that ORG 25935 
decreased ethanol intake and ethanol preference, as compared 
with vehicle, without affecting water intake. This effect was 
dose-dependent, developed gradually, and was sustained for up 
to 40 days, even after the introduction of an alcohol-deprivation 
period. The findings suggest that ORG 25935, and possibly 
other GlyT-1 inhibitors as well, could provide a new 
pharmacological treatment strategy for alcohol dependence or 
abuse [92]. 
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Fig. (10). Chemical structure of ORG 25935. 
BRAIN IMAGING OF GLyT-1 IN THE BRAIN 
  The distribution, density, and activity of GlyT-1 in the 
living human brain can be visualized noninvasively by the 
specific radioligands and positron emission tomography 
(PET), and single photon computed tomography (SPECT), 
and the receptor binding can be quantified by appropriate 
tracer kinetic models, which can be modified and simplified 
for particular applications. Therefore, in vivo PET/SPECT 
imaging of GlyT-1 in the human brain provides a method for 
quantitative study of the GlyT-1-related pathophysiology in 
schizophrenia. Researchers at Merck developed the novel 
radioligand [
35S](S)-2-amino-4-chloro-N-(1-(4-phenyl-1-
(propylsulfonyl)piperidin-4-yl)ethyl)benzamide ([
35S]AC-
PPB: Kd=1.9 nM) (Fig. 11) for GlyT-1 in the brain. 
Autoradiographic studies of rat and rhesus brain slices with 
[
35S]ACPPB showed that specific binding sites were 
plentiful and nonhomogeneously distributed, with high 
levels of binding in the brainstem, cerebellar white matter, 
thalamus, cortical white matter and spinal cord gray matter. 
In vivo studies demonstrated displaceable binding of 
[
35S]ACPPB in rat brain tissues following intravenous 
administration of this radioligand [93]. Investigators at 
Merck also developed the novel PET ligand [
18F] 2,4-
dichloro-N- ((1-(propylsulfonyl)-4-(6-fluoropyridin-2-yl) 
piperidin-4-yl)methyl)benzamide (CFPyPB) (Fig. 11) for 
GlyT-1 in the human brain [94].  
  In addition, researchers at Glaxo developed the PET 
ligand [
11C]GSK 931145 (Fig. 12) for GlyT-1 in the human 
brain [95,96]. [
18F]CFPyPB and [
11C]GSK 931145 would be 
potential PET ligands for in vivo visualization of GlyT-1 in 
the living human brain with PET. These PET ligands 
represent a new tool for the evaluation of glutamatergic 
neurotransmission in the pathophysiology of neuropsy-
chiatric diseases, including schizophrenia. Glycine Transport Inhibitors for the Treatment of Schizophrenia  The Open Medicinal Chemistry Journal, 2010, Volume 3    15 
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Fig. (11). Chemical structures of [
35S](S)-2-amino-4-chloro-N-(1-
(4-phenyl-1-(propylsulfonyl)piperidin-4-yl)ethyl)benzamide ([
35S] 
ACPPB), and [
18F] 2,4-dichloro-N- ((1-(propylsulfonyl)-4-(6-
fluoropyridin-2-yl) piperidin-4-yl)methyl)benzamide ([
18F]CFPy 
PB). 
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Fig. (12). Chemical structure of [
11C]GSK 931145. 
 
CLINICAL STUDY OF GLyT-1 INHIBITORS 
  Sarcosine is generated by the enzymatic transfer of a 
methyl group from S-adenosylmethionine to glycine, and this 
reaction is catalyzed by the enzyme glycine N-
methyltransferase [97,98]. Recently, sarcosine was identified 
as a biomarker that is highly increased during prostate cancer 
progression to metastasis and can be detected non-invasively 
in urine [99]. Interestingly, a recent population-based, 
nested, case-controlled study demonstrated a 40.7% lower 
risk of prostate cancer in male patients with schizophrenia 
[100]. It is thus likely that the sarcosine pathway plays a role 
in the lower risk for prostate cancer in male subjects with 
schizophrenia, although further detailed studies will be 
necessary to confirm this hypothesis [98]. 
  Sarcosine is a safe drug, since it is synthesized in the 
human body. In fact, treatment with sarcosine (2 g/day) can 
benefit schizophrenic patients also being treated with 
antipsychotics, including risperidone [101], but not clozapine 
[102]. A randomized, double-blind, placebo-controlled study 
demonstrated that members of a sarcosine (2 g/day) group 
showed greater reductions in their Positive and Negative 
Syndrome Scale (PANSS) total scores than members of a 
placebo group or D-serine (2 g/day) group, suggesting that 
sarcosine is superior to D-serine in that benefits both patients 
with long-term stable disease and also acutely ill persons 
with schizophrenia [103]. Furthermore, a randomized, 
double-blind study reported that sarcosine (2 g/day) alone 
was effective in the treatment of acutely symptomatic drug-
free patients with schizophrenia [104]. Further large-sized, 
placebo-controlled, dose-finding studies are needed to fully 
assess the effects of sarcosine, since these reports regarding 
the beneficial effects of sarcosine were based on small 
studies from the same group in Taiwan. In contrast, Zhang et 
al. [105] reported that sarcosine is an NMDA receptor co-
agonist that differs from glycine, suggesting that co-agonistic 
activity at the NMDA receptors of sarcosine may, in part, be 
involved in the clinical benefits of this drug in schizophrenia. 
Nonetheless, all these findings suggest that GlyT-1 inhibition 
could be a novel pharmacotherapeutic target for enhancing 
NMDA receptor function.  
  Very recently, Liem-Moolenaar et al. [106] reported the 
effects of the GlyT-1 inhibitor R 231857 (Fig. 13) on the 
CNS and on scopolamine-induced impairments in cognitive 
and psychomotor function in healthy subjects. R231857 had 
some small effects on scopolamine-induced CNS-
impairment, which were also not clearly dependent on dose. 
Scopolamine proved to be an accurate, reproducible and safe 
model for the induction of CNS impairment by an 
anticholinergic mechanism. R231857 lacked consistent dose-
related effects in this study, probably because the CNS 
concentrations were too low to produce significant/re-
producible CNS effects or to affect the scopolamine 
challenge in healthy volunteers. The effects of higher doses 
in healthy volunteers and the clinical efficacy in patients 
remain to be established. To date, clinical findings with 
GlyT-1 inhibitors are limited because of the early stage of 
development of the most high-affinity compounds. 
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Fig. (13). Chemical structure of R231857. 
 
CONCLUDING REMARKS 
  As described above, the glycine modulatory sites on 
NMDA receptors are among the most attractive targets for 
developing potential therapeutic drugs for the treatment of 
schizophrenia. One means of enhancing NMDA receptor 
function would be to pharmacologically increase synaptic 
glycine levels by GlyT-1 inhibitors. At present, a number of 
pharmaceutical companies are developing novel and 16    The Open Medicinal Chemistry Journal, 2010, Volume 3  Kenji Hashimoto 
selective GlyT-1 inhibitors for the treatment of 
schizophrenia [43-55]. Gaining a better understanding of the 
role of GlyT-1 in the treatment of schizophrenia is expected 
to provide new perspectives for treating this disorder. 
Finally, the pharmacological modulation of glycine 
modulatory sites on NMDA receptors by non-sarcosine-
derived GlyT-1 inhibitors could be beneficial in the 
treatment of the cognitive deficits and psychosis associated 
with several psychiatric diseases, including schizophrenia.  
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